LifeSci Startup’s Post

Which of the following is the best initial management for diabetes in a patient with a BMI of 38? Prescribe oral antidiabetic medication Recommend lifestyle modifications, including diet and exercise Initiate insulin therapy Refer the patient to a bariatric surgery specialist Explanation: The best initial management for diabetes in a patient with a BMI of 38 is to recommend lifestyle modifications, including diet and exercise. This approach is known as the first-line therapy for managing type 2 diabetes. Option 1) Prescribing oral antidiabetic medication may sometimes be necessary, but it is not the best initial management strategy. Lifestyle modifications should be attempted first before considering medication. Option 3) Initiating insulin therapy is not the first-line treatment for type 2 diabetes. Insulin therapy is usually reserved for patients who do not respond to lifestyle modifications and oral medications. Option 4) Referring the patient to a bariatric surgery specialist may be an option for individuals with severe obesity and poorly controlled diabetes. However, it is not the best initial management strategy and should be considered only after lifestyle modifications and medication have been attempted.

What is the most common cause of Charcot arthropathy? Trauma Diabetes mellitus Rheumatoid arthritis Osteoarthritis Explanation: Diabetes mellitus Charcot arthropathy, also known as neuropathic arthropathy, is a condition characterised by progressive degeneration of a joint, usually in the foot or ankle, due to underlying neuropathy. It is most commonly seen in individuals with diabetes mellitus. 1) Trauma: While trauma can lead to joint damage and degeneration, it is not the primary cause of Charcot arthropathy. This condition occurs due to underlying neuropathy, which is commonly seen in individuals with diabetes. 2) Diabetes mellitus: This is the correct answer. Diabetes mellitus is the most common cause of Charcot arthropathy. Chronic high blood sugar levels in diabetes can lead to peripheral neuropathy, which affects the nerves supplying the joints. The loss of sensation and proprioception in the affected joint can result in repeated trauma, leading to joint destruction and Charcot arthropathy. 3) Rheumatoid arthritis: Rheumatoid arthritis is an autoimmune disease that primarily affects the joints. While it can cause joint deformities and destruction, it is not a common cause of Charcot arthropathy. The underlying mechanism and pathophysiology of Charcot arthropathy differ from those of rheumatoid arthritis. 4) Osteoarthritis: Osteoarthritis is a degenerative joint disease characterised by the breakdown of joint cartilage. It is not a common cause of Charcot arthropathy. Unlike osteoarthritis, Charcot arthropathy is associated with underlying neuropathy, typically seen in diabetes mellitus.

knownwell acquires Alfie Health to enhance metabolic health offerings - MobiHealthNews #Acquisition: KnownWell acquires Alfie Health KnownWell, a leading healthcare company, has acquired Alfie Health to enhance its metabolic health offerings. This acquisition aims to expand KnownWell's portfolio and provide comprehensive solutions for metabolic health management. #KnownWell #AlfieHealth #Benefits of Acquisition The acquisition of Alfie Health will enable KnownWell to offer a wider range of services and solutions for managing metabolic health conditions. This will benefit patients by providing them with more personalized and effective care options. #MetabolicHealth #HealthcareSolutions #Integration Process KnownWell is currently in the process of integrating Alfie Health into its existing infrastructure. This involves combining the strengths of both companies to create a seamless experience for patients ai.mediformatica.com #health #knownwell #platform #management #clinical #metabolichealth #alfiehealth #clinicaldecision #clinicaldecisionsupport #decisionsupport #obesityrx #provider #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3zcULaJ)

Hot off the Press! Medasense has reached a agreement with Panakeia, LLC to distribute Medasense's PMD-200 device to United States government institutions. The collaboration between Medasense and Panakeia represents a significant step forward in pain management technology for the US. By harnessing the power of innovative solutions like the PMD-200, healthcare providers can deliver personalized care to servicemen and women, and veterans, optimizing recovery and reducing postoperative pain. Read the full press release here: https://lnkd.in/ePmdR92i #painmanagement #patientcare #nociceptionmonitoring

From a perspective piece published in today's New England Journal of Medicine about direct-to-consumer models for glucagon-like peptide-1 (GLP-1) receptor agonists: "We propose a framework for identifying the features of online DTC [direct-to-consumer] platforms that would promote safe, reliable, and evidence-based care, based on experiences with testosterone therapy and telemedicine standards of care [..]. We believe it will be important for researchers to better establish the frequency of DTC prescribing, for policymakers to monitor the prescribing practices of DTC platforms in order to identify and address potential risks, and for clinicians and health care systems to ask their patients about use of DTC platforms and to consider partnering with reputable weight-management companies and online platforms in order to augment traditional care with approaches that could increase medication access, patient engagement, and points of contact. A national certification program for DTC platforms for antiobesity medications could provide a framework for standardizing the use of best practices and encouraging the adoption of patient-centered outcome measures. [..] DTC prescribing is ultimately a reaction to the shortcomings of traditional models of care; reform that integrates reputable sources of DTC prescribing and expands insurance coverage to various platforms could help create a system in which multiple models operate in sync. [..] Although the movement toward online DTC platforms may be inevitable, the concerns that have been associated with prescribing of testosterone therapy can be addressed [e.g., short courses of treatment rather than chronic hormone replacement, guideline-discordant care]. With proactive oversight of industry and closer integration between DTC platforms and traditional health care systems, we believe that better access will in fact translate into better care." I currently work for PlushCare (a subsidiary of Accolade, Inc.), a national telemedicine-only practice that markets itself toward patients interested in accessing GLP-1 agonists to help lose weight.

Recommended read! 📖 𝐓𝐡𝐞 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐏𝐚𝐢𝐧 𝐑𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐄𝐧𝐡𝐚𝐧𝐜𝐢𝐧𝐠 𝐖𝐨𝐮𝐧𝐝 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 This article discusses the impact of pain on chronic wound healing and the impact of MedTech innovation in addressing this burden: https://lnkd.in/eEmEN4YR For information on how the geko™ device reduces pain¹, accelerates healing² and improves concordance to standard of care³ visit: https://lnkd.in/gTZnRBXZ #VLU #Woundmanagement #MedTech #MedicalTechnology 1 – Jones N et al. Br J Nurs 2018; 27(20): S16-S21 2 – Bull R et al. Int Wound J. 2023; 1–9 3 – Harris C et al. Int Wound J 2017; 14: 1189–98.

🌿 Discover the power of DMSO! 🌿 Dimethyl sulfoxide (DMSO) offers a myriad of applications in medicine, industry, and research. Known for its unique properties, it provides potential health benefits when used correctly. Learn more about DMSO's uses, health benefits, and safety guidelines in our latest article! #DMSO #HealthBenefits #SafetyFirst #HowlerMag 🔗 https://lnkd.in/ejzk6rBK

🚀 Global Smart Pills Market to Witness 10-12% Growth from 2024 to 2029 🌍 The smart pills market is on the rise, driven by key trends such as: 🔹 Increasing prevalence of chronic diseases 📈 🔹 Advances in capsule endoscopy 💊 🔹 Growing demand for non-invasive diagnostics 🔬 🔹 A focus on patient compliance and personalized medicine 👩⚕️👨⚕️ 🔹 Favorable government & regulatory frameworks 🏛️ 🌎 North America stands out as a key region, bolstered by rising healthcare demands and innovation. Key players shaping the market include: CapsoVision, Inc., Medtronic Plc , Olympus Corporation, Check-Cap Ltd., Otsuka Holdings Co., Ltd., IntroMedic Co.,Ltd, etectRx, AnX Robotica Corp, BodyCAP, and more. Want to dive deeper? Download the sample report here: https://lnkd.in/dzM7KpXe #SmartPills #MedTech #Diagnostics #PatientCare #MedicalDevices #MediTech #ChronicDiseases #NonInvasiveDiagnostics #PatientCompliance #CapsuleEndoscopy #ChronicDisease #PersonalizedMedicine #GeriatricCare #HealthcareTechnology #RegulatoryFramework #LifeSciences #HealthTech #MedicalInnovation #DigitalHealth #MedTechSolutions #PharmaTech #Biotech #HealthcareTrends #PatientMonitoring #HealthCareSolutions #InnovationInHealthcare #WearableTech #MedicalResearch #DrugDelivery #NonInvasiveTechnology #ColorectalCancer #NeurologicalDisorders #DiabetesCare #CancerDiagnostics #Hospitals #DiagnosticCenters #HomeHealthcare #ResearchInstitutes #DigitalPills

After three exciting phases in the past decade, strong growth in FY12–17, steady growth in FY17–20 and high Covid-led growth in FY21-22, moving forward we expect the Indian diagnostic market to normalize to 11.5 percent. Read the exclusive story. #growth #strong #diagnostic #market #normalize #Covid #steady #treatment #landscape #productivity #initiatives #clinicians #network #trajectory #healthcare

When should a diabetic patient be screened for diabetic retinopathy? Every 2 years for both T1D and T2D patients Every 5 years for T1D patients and every 2 years for T2D patients Every year for T1D patients and every 2 years for T2D patients Every year for both T1D and T2D patients Explanation: Every year for T1D patients and every 2 years for T2D patients Diabetic retinopathy is a complication of diabetes that affects the eyes. Regular screening is crucial to detect and manage this condition. For patients with Type 1 Diabetes (T1D), annual screening is recommended due to the higher risk and early onset of diabetic retinopathy. On the other hand, for patients with Type 2 Diabetes (T2D), screening every 2 years is recommended unless additional risk factors are present, such as a history of retinopathy or poor glycemic control, which may require more frequent screenings. Regular eye examinations are essential to identify any signs of diabetic retinopathy and initiate timely treatment to prevent vision loss.